{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:17:30Z","timestamp":1790007450255,"version":"4.0.1"},"reference-count":52,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:00:00Z","timestamp":1551657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2019,11,15]]},"abstract":"<jats:p>We analysed patterns in the incidence of cervical intraepithelial neoplasia grades 2 and 3 (CIN2, CIN3) and adenocarcinoma <jats:italic>in situ<\/jats:italic> (AIS) by age and histology in 1992\u20132016 in Norway and described changes in screening tests. Incident cases of CIN2, CIN3, AIS and cervical cancer were identified in the Cancer Registry of Norway, as were all women with at least one screening test. The annual percentage change statistic was used to assess point estimates and changes in age\u2010specific and age\u2010standardised incidence rates (IR). Women aged 25\u201329\u2009years had the highest incidence of cervical precancerous lesions (CIN2: 192.9\/10, CIN3: 737.2\/10, AIS: 32.5\/10<jats:sup>5<\/jats:sup> in 2016). The IR of CIN2 increased for all screening ages (25\u201369\u2009years) from 3.6% to 6.7% per year. CIN3 incidence increased by 1.6% (95% confidence interval [CI] 0.6\u20132.6) annually. A steep increase in AIS incidence was observed in all age groups (7.1% per year, 95% CI 5.3\u20138.8). Changes in screening tests and the histological verification of cervical precancerous lesions alone cannot explain the steady increase in incidence we observed over the 25\u2010year study period, and increased exposure to human papillomavirus (HPV) likely plays a role. Age\u2010appropriate treatment of screening\u2010detected cervical precancerous lesions is needed for effective cervical cancer control while avoiding overtreatment and related health risks. In order to perform an appropriate harm\u2010benefit evaluation of cervical cancer control efforts, detailed information on screening technology and background risks, including HPV vaccination status, is needed to create optimal public health policy.<\/jats:p>","DOI":"10.1002\/ijc.32195","type":"journal-article","created":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T08:25:04Z","timestamp":1549614304000},"page":"2629-2638","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016"],"prefix":"10.1002","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6849-202X","authenticated-orcid":false,"given":"Madleen","family":"Orumaa","sequence":"first","affiliation":[{"name":"Department of Research Cancer Registry of Norway  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarit K","family":"Leinonen","sequence":"additional","affiliation":[{"name":"Department of Research Cancer Registry of Norway  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Research Cancer Registry of Norway  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"M\u00f8ller","sequence":"additional","affiliation":[{"name":"Department of Registration Cancer Registry of Norway  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor \u00c5ge","family":"Myklebust","sequence":"additional","affiliation":[{"name":"Department of Registration Cancer Registry of Norway  Oslo Norway"},{"name":"Department of Research and Innovation M\u00f8re and Romsdal Hospital Trust  \u00c5lesund Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4100-4855","authenticated-orcid":false,"given":"Mari","family":"Nyg\u00e5rd","sequence":"additional","affiliation":[{"name":"Department of Research Cancer Registry of Norway  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,4]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31043"},{"key":"e_1_2_6_4_1","volume-title":"European guidelines for quality assurance in cervical cancer screening","author":"IARC","year":"2008"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.290"},{"key":"e_1_2_6_6_1","unstructured":"Cancer in Norway 2016 \u2010 Cancer incidence mortality survival and prevalence in Norway. The Cancer Registry of Norway 2017."},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/jms.9.2.86"},{"key":"e_1_2_6_8_1","unstructured":"Annual report 2013\u20132014. Cervical Cancer screening [In Norwegian]. The Cancer Registry of Norway 2015."},{"key":"e_1_2_6_9_1","unstructured":"Annual report 2015. Cervical Cancer screening [In Norwegian]. The Cancer Registry of Norway 2016."},{"key":"e_1_2_6_10_1","unstructured":"Annual report 2016. Cervical Cancer screening [In Norwegian]. The Cancer Registry of Norway 2018."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-12-1406"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27485"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.362"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088323"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019005"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.12.018"},{"key":"e_1_2_6_17_1","unstructured":"Quality assurance manual in Cervical Cancer Screening Programme [In Norwegian]. The Cancer Registry of Norway 2012."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.037"},{"key":"e_1_2_6_19_1","volume-title":"International classification of diseases for oncology (ICD\u2010O)","author":"WHO","year":"2013"},{"key":"e_1_2_6_20_1","volume-title":"WHO classification of Tumours of the female reproductive organs","author":"IARC","year":"2014"},{"key":"e_1_2_6_21_1","unstructured":"Norwegian SNOMED Coding System available at:https:\/\/kreftregisteret.no\/Registrene\/Innrapportering\/Rapportering\u2010av\u2010patologiinformasjon\/. Retrieved June 6 2018."},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29541"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-85849-9"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X1101000405"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000296488.85807.b3"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-10-201111150-00376"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2014.932433"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-015-0603-7"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0969141315580836"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10508-009-9494-6"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000231"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2017-053397"},{"key":"e_1_2_6_33_1","volume-title":"Annual report. Blood brone and sexually transmitted diseases in Norway 2016 [In Norwegian]","author":"Norwegian Institute of Public Health","year":"2017"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2017.08.006"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k499"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181e4629f"},{"key":"e_1_2_6_37_1","volume-title":"Cervix cancer screening","author":"IARC, IARC Handbooks of Cancer Prevention","year":"2005"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.09.010"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-12-0162"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1086\/657321"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2015.06.006"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70103-7"},{"key":"e_1_2_6_43_1","first-page":"Cd012847","article-title":"Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease","volume":"11","author":"Kyrgiou M","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000001777"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0000000000000418"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60551-5"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3609"},{"key":"e_1_2_6_48_1","unstructured":"Norwegian Institute of Public Health HPV vaccination coverage among girls born in 2004 available at:https:\/\/fhi.no\/hn\/helseregistre-og-registre\/sysvak\/dekkningsstatistikk\/. Retrieved July 10 2018."},{"key":"e_1_2_6_49_1","unstructured":"Norwegian Institute of Public Health HPV vaccination coverage among women born 1991\u20131996 available at:http:\/\/norgeshelsa.no\/norgeshelsa\/. Retrieved July 10 2018."},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2013.09.002"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2018.1497296"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29266"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2017.07.027"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.32195","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.32195","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.32195","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.32195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T05:36:24Z","timestamp":1694324184000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.32195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,4]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,11,15]]}},"alternative-id":["10.1002\/ijc.32195"],"URL":"https:\/\/doi.org\/10.1002\/ijc.32195","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,4]]},"assertion":[{"value":"2018-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}